Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8
Avadel Pharmaceuticals (Nasdaq: AVDL) has announced it will host a conference call and live webcast on January 8, 2025, at 4:30 p.m. ET to provide a corporate update and discuss preliminary unaudited financial results for Q4 and full-year 2024. The webcast will be accessible through the company's investor relations website section at www.avadel.com, where it will remain archived for 90 days after the event. Participants are encouraged to register for the conference call at least 10 minutes before the start time.
Avadel Pharmaceuticals (Nasdaq: AVDL) ha annunciato che ospiterà una conferenza telefonica e un webcast dal vivo il 8 gennaio 2025, alle 16:30 ET per fornire un aggiornamento aziendale e discutere i risultati finanziari preliminari non auditati per il quarto trimestre e l'intero anno 2024. Il webcast sarà accessibile attraverso la sezione delle relazioni con gli investitori sul sito web dell'azienda, www.avadel.com, dove rimarrà archiviato per 90 giorni dopo l'evento. Si incoraggiano i partecipanti a registrarsi per la conferenza telefonica almeno 10 minuti prima dell'orario di inizio.
Avadel Pharmaceuticals (Nasdaq: AVDL) ha anunciado que llevará a cabo una conferencia telefónica y un webcast en vivo el 8 de enero de 2025, a las 4:30 p.m. ET para proporcionar una actualización corporativa y discutir los resultados financieros preliminares no auditados para el cuarto trimestre y el año completo 2024. El webcast estará accesible a través de la sección de relaciones con los inversores en el sitio web de la empresa, www.avadel.com, donde permanecerá archivado durante 90 días después del evento. Se anima a los participantes a registrarse para la conferencia telefónica al menos 10 minutos antes de la hora de inicio.
아바델 제약 (Nasdaq: AVDL)은 2025년 1월 8일 오후 4시 30분 ET에 기업 업데이트를 제공하고 2024년 4분기 및 전체 연도의 예비 감사 없는 재무 결과를 논의하기 위해 전화 회의 및 라이브 웨비나를 개최할 것이라고 발표했습니다. 웨비나는 회사의 투자자 관계 웹사이트 섹션인 www.avadel.com을 통해 접근할 수 있으며, 이벤트 후 90일 동안 아카이브로 남아 있을 것입니다. 참가자는 시작 시간 10분 전까지 전화 회의에 등록할 것을 권장합니다.
Avadel Pharmaceuticals (Nasdaq: AVDL) a annoncé qu'elle tiendra une conférence téléphonique et un webinaire en direct le 8 janvier 2025 à 16h30 ET pour fournir une mise à jour de l'entreprise et discuter des résultats financiers préliminaires non audités pour le quatrième trimestre et l'année complète 2024. Le webinaire sera accessible via la section des relations investisseurs sur le site web de l'entreprise, www.avadel.com, où il restera archivé pendant 90 jours après l'événement. Les participants sont encouragés à s'inscrire pour la conférence téléphonique au moins 10 minutes avant l'heure de début.
Avadel Pharmaceuticals (Nasdaq: AVDL) hat angekündigt, dass am 8. Januar 2025 um 16:30 Uhr ET eine Telefonkonferenz und ein Live-Webcast stattfinden werden, um ein Unternehmensupdate zu geben und die vorläufigen, nicht testierten Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 zu diskutieren. Der Webcast wird über den Bereich Investor Relations der Unternehmenswebsite unter www.avadel.com zugänglich sein, wo er 90 Tage nach der Veranstaltung archiviert bleibt. Die Teilnehmer werden ermutigt, sich mindestens 10 Minuten vor Beginn der Telefonkonferenz anzumelden.
- None.
- None.
DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, January 8, 2025, to provide a corporate update and discuss the Company's preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024.
A live audio webcast of the call can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.
Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionaq.com
(212) 698-8696
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
FAQ
When will Avadel Pharmaceuticals (AVDL) release its Q4 and full-year 2024 preliminary results?
How can investors access AVDL's Q4 2024 earnings conference call?
How long will AVDL's Q4 2024 earnings webcast be available for replay?
What financial information will AVDL discuss in its January 8, 2025 update?
